The urologist view of BPH progression: results of an international survey.
OBJECTIVE
To assess the opinion amongst the international urological community on whether benign prostatic hyperplasia (BPH) is a progressive disease.


METHODS
A 15-item questionnaire was distributed to the mailing list of the publication European Urology Today as well as being accessed through the website of the European Association of Urology (EAU). The survey included questions on: whether BPH was a progressive disorder; what evidence there was to support this, including clinical parameters that could be identified; risk factors for progression; and prevention of progression.


RESULTS
A total of 472 completed questionnaires from 47 countries were evaluated. Overall, the urologists surveyed agreed that BPH was a progressive disease, and that some patients were more prone to this than others. Increased post-void residual urine, reduced flow rate, increased urinary symptoms and urodynamic evidence of obstruction were considered to be the most significant risk factors for progression. Half of the urologists surveyed considered that current medical therapies could prevent progression of BPH, while a significant proportion thought that surgery was an effective preventative measure.


CONCLUSIONS
BPH, although a benign disease, has a considerable impact on the patient's quality of life. Its progressive nature and the identification of risk factors for progression warrant further investigation. In the future, there is likely to be a shift in the paradigm from treatment of BPH complications to include the prevention of BPH progression.
Djavan
B
B
Department of Urology, University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria. bdjavan@hotmail.com
Nickel
J C
JC
de la Rosette
J
J
Abrams
P
P
D000328:Adult; D018450:Disease Progression; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D012307:Risk Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014572:Urology / Q000592:standards*